Abiraterone
The serum concentration of Procainamide can be increased when it is combined with Abiraterone.
Albuterol
Salbutamol may increase the QTc-prolonging activities of Procainamide.
Alfuzosin
Alfuzosin may increase the QTc-prolonging activities of Procainamide.
Advertisement
Amantadine
Amantadine may increase the QTc-prolonging activities of Procainamide.
Amiodarone
Amiodarone may increase the QTc-prolonging activities of Procainamide.
Amitriptyline
Amitriptyline may increase the QTc-prolonging activities of Procainamide.
Advertisement
Amoxapine
Amoxapine may increase the QTc-prolonging activities of Procainamide.
Anagrelide
The risk or severity of QTc prolongation can be increased when Anagrelide is combined with Procainamide.
Apomorphine
Apomorphine may increase the QTc-prolonging activities of Procainamide.
Advertisement
Arformoterol
Arformoterol may increase the QTc-prolonging activities of Procainamide.
Aripiprazole
Aripiprazole may increase the QTc-prolonging activities of Procainamide.
Arsenic Trioxide
The risk or severity of QTc prolongation can be increased when Procainamide is combined with Arsenic trioxide.
Artemether
The risk or severity of QTc prolongation can be increased when Procainamide is combined with Artemether.
Asenapine
The risk or severity of QTc prolongation can be increased when Procainamide is combined with Asenapine.
Atazanavir
Atazanavir may increase the QTc-prolonging activities of Procainamide.
Atomoxetine
Atomoxetine may increase the QTc-prolonging activities of Procainamide.
Atracurium
Procainamide may increase the neuromuscular blocking activities of Atracurium.
Atracurium Besylate
Procainamide may increase the neuromuscular blocking activities of Atracurium besylate.
Azithromycin
Azithromycin may increase the QTc-prolonging activities of Procainamide.
Bedaquiline
Bedaquiline may increase the QTc-prolonging activities of Procainamide.
Betaxolol
The metabolism of Procainamide can be decreased when combined with Betaxolol.
Bortezomib
Bortezomib may increase the QTc-prolonging activities of Procainamide.
Bupropion
The metabolism of Procainamide can be decreased when combined with Bupropion.
Buserelin
Buserelin may increase the QTc-prolonging activities of Procainamide.
Celecoxib
The metabolism of Procainamide can be decreased when combined with Celecoxib.
Ceritinib
Ceritinib may increase the QTc-prolonging activities of Procainamide.
Chloroquine
Chloroquine may increase the QTc-prolonging activities of Procainamide.
Chlorpromazine
Chlorpromazine may increase the QTc-prolonging activities of Procainamide.
Cholecalciferol
The metabolism of Procainamide can be decreased when combined with Cholecalciferol.
Cimetidine
The serum concentration of Procainamide can be increased when it is combined with Cimetidine.
Cinacalcet
The metabolism of Procainamide can be decreased when combined with Cinacalcet.
Ciprofloxacin
Ciprofloxacin may increase the QTc-prolonging activities of Procainamide.
Cisapride
The risk or severity of QTc prolongation can be increased when Cisapride is combined with Procainamide.
Cisatracurium
Procainamide may increase the neuromuscular blocking activities of Cisatracurium besylate.
Citalopram
The metabolism of Procainamide can be decreased when combined with Citalopram.
Clarithromycin
Clarithromycin may increase the QTc-prolonging activities of Procainamide.
Clemastine
The metabolism of Procainamide can be decreased when combined with Clemastine.
Clobazam
The metabolism of Procainamide can be decreased when combined with Clobazam.
Clomipramine
Clomipramine may increase the QTc-prolonging activities of Procainamide.
Clotrimazole
The metabolism of Procainamide can be decreased when combined with Clotrimazole.
Clozapine
Clozapine may increase the QTc-prolonging activities of Procainamide.
Cobicistat
The serum concentration of Procainamide can be increased when it is combined with Cobicistat.
Cocaine
The metabolism of Procainamide can be decreased when combined with Cocaine.
Crizotinib
Crizotinib may increase the QTc-prolonging activities of Procainamide.
Dabrafenib
Dabrafenib may increase the QTc-prolonging activities of Procainamide.
Darifenacin
The metabolism of Procainamide can be decreased when combined with Darifenacin.
Darunavir
The serum concentration of Procainamide can be increased when it is combined with Darunavir.
Dasatinib
Dasatinib may increase the QTc-prolonging activities of Procainamide.
Dasatinib Anhydrous
Dasatinib may increase the QTc-prolonging activities of Procainamide.
Degarelix
Degarelix may increase the QTc-prolonging activities of Procainamide.
Delavirdine
The metabolism of Procainamide can be decreased when combined with Delavirdine.
Desflurane
Desflurane may increase the QTc-prolonging activities of Procainamide.
Desipramine
Desipramine may increase the QTc-prolonging activities of Procainamide.
Deutetrabenazine
Procainamide may increase the QTc-prolonging activities of Deutetrabenazine.
Diphenhydramine
Diphenhydramine may increase the QTc-prolonging activities of Procainamide.
Disopyramide
The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Procainamide.
Dofetilide
The risk or severity of QTc prolongation can be increased when Dofetilide is combined with Procainamide.
Dolasetron
Dolasetron may increase the QTc-prolonging activities of Procainamide.
Domperidone
The risk or severity of QTc prolongation can be increased when Procainamide is combined with Domperidone.
Dothiepin
The metabolism of Procainamide can be decreased when combined with Dosulepin.
Doxacurium Chloride
Procainamide may increase the neuromuscular blocking activities of Doxacurium chloride.
Doxepin
Doxepin may increase the QTc-prolonging activities of Procainamide.
Dronedarone
The risk or severity of QTc prolongation can be increased when Procainamide is combined with Dronedarone.
Droperidol
Droperidol may increase the QTc-prolonging activities of Procainamide.
Duloxetine
The metabolism of Procainamide can be decreased when combined with Duloxetine.
Eliglustat
The risk or severity of QTc prolongation can be increased when Procainamide is combined with Eliglustat.
Eribulin
Eribulin may increase the QTc-prolonging activities of Procainamide.
Erythromycin
Erythromycin may increase the QTc-prolonging activities of Procainamide.
Escitalopram
The risk or severity of QTc prolongation can be increased when Procainamide is combined with Escitalopram.
Ezogabine
Ezogabine may increase the QTc-prolonging activities of Procainamide.
Famotidine
Famotidine may increase the QTc-prolonging activities of Procainamide.
Felbamate
Felbamate may increase the QTc-prolonging activities of Procainamide.
Fingolimod
Fingolimod may increase the arrhythmogenic activities of Procainamide.
Flecainide
Flecainide may increase the QTc-prolonging activities of Procainamide.
Fluconazole
Fluconazole may increase the QTc-prolonging activities of Procainamide.
Fluoxetine
The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Procainamide.
Flupenthixol
The risk or severity of QTc prolongation can be increased when Flupentixol is combined with Procainamide.
Fluvoxamine
The metabolism of Procainamide can be decreased when combined with Fluvoxamine.
Formoterol
Formoterol may increase the QTc-prolonging activities of Procainamide.
Foscarnet
Foscarnet may increase the QTc-prolonging activities of Procainamide.
Gadobenate
Gadobenic acid may increase the QTc-prolonging activities of Procainamide.
Galantamine
Galantamine may increase the QTc-prolonging activities of Procainamide.
Gallamine Triethiodide
Procainamide may increase the neuromuscular blocking activities of Gallamine Triethiodide.
Gemifloxacin
Gemifloxacin may increase the QTc-prolonging activities of Procainamide.
Gemifloxacin Mesylate
Gemifloxacin may increase the QTc-prolonging activities of Procainamide.
Goserelin
Goserelin may increase the QTc-prolonging activities of Procainamide.
Granisetron
Granisetron may increase the QTc-prolonging activities of Procainamide.
Haloperidol
Haloperidol may increase the QTc-prolonging activities of Procainamide.
Histrelin
Histrelin may increase the QTc-prolonging activities of Procainamide.
Hydroxyzine
Hydroxyzine may increase the QTc-prolonging activities of Procainamide.
Ibandronate
Ibandronate may increase the QTc-prolonging activities of Procainamide.
Ibandronic Acid
Ibandronate may increase the QTc-prolonging activities of Procainamide.
Ibutilide
The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Procainamide.
Iloperidone
The risk or severity of QTc prolongation can be increased when Procainamide is combined with Iloperidone.
Imipramine
Imipramine may increase the QTc-prolonging activities of Procainamide.
Indacaterol
Indacaterol may increase the QTc-prolonging activities of Procainamide.
Indapamide
Indapamide may increase the QTc-prolonging activities of Procainamide.
Indinavir
The metabolism of Procainamide can be decreased when combined with Indinavir.
INDINAVIR ANHYDROUS
The metabolism of Procainamide can be decreased when combined with Indinavir.
Isoflurane
Isoflurane may increase the QTc-prolonging activities of Procainamide.
Isoniazid
The metabolism of Procainamide can be decreased when combined with Isoniazid.
Isradipine
Isradipine may increase the QTc-prolonging activities of Procainamide.
Itraconazole
Itraconazole may increase the QTc-prolonging activities of Procainamide.
Ivabradine
Procainamide may increase the QTc-prolonging activities of Ivabradine.
Ketoconazole
Ketoconazole may increase the QTc-prolonging activities of Procainamide.
Lamotrigine
The serum concentration of Procainamide can be increased when it is combined with Lamotrigine.
Lapatinib
Lapatinib may increase the QTc-prolonging activities of Procainamide.
Lenvatinib
Lenvatinib may increase the QTc-prolonging activities of Procainamide.
Lenvatinib Mesylate
Lenvatinib may increase the QTc-prolonging activities of Procainamide.
Leuprolide
Leuprolide may increase the QTc-prolonging activities of Procainamide.
Levofloxacin
Levofloxacin may increase the QTc-prolonging activities of Procainamide.
Levofloxacin Anhydrous
Levofloxacin may increase the QTc-prolonging activities of Procainamide.
Lithium
Lithium may increase the QTc-prolonging activities of Procainamide.
Lithium Cation
Lithium may increase the QTc-prolonging activities of Procainamide.
Lopinavir
The risk or severity of QTc prolongation can be increased when Procainamide is combined with Lopinavir.
Lorcaserin
The metabolism of Procainamide can be decreased when combined with Lorcaserin.
Lumefantrine
The risk or severity of QTc prolongation can be increased when Procainamide is combined with Lumefantrine.
Lurasidone
Lurasidone may increase the QTc-prolonging activities of Procainamide.
Macimorelin
Procainamide may increase the QTc-prolonging activities of Macimorelin.
Manidipine
The metabolism of Procainamide can be decreased when combined with Manidipine.
Maprotiline
Maprotiline may increase the QTc-prolonging activities of Procainamide.
Mefloquine
Mefloquine may increase the QTc-prolonging activities of Procainamide.
Methadone
Methadone may increase the QTc-prolonging activities of Procainamide.
Methotrimeprazine
The metabolism of Procainamide can be decreased when combined with Methotrimeprazine.
Metoclopramide
Metoclopramide may increase the QTc-prolonging activities of Procainamide.
Metocurine
Procainamide may increase the neuromuscular blocking activities of Metocurine.
Metocurine iodide
Procainamide may increase the neuromuscular blocking activities of Metocurine Iodide.
Metoprolol
The metabolism of Procainamide can be decreased when combined with Metoprolol.
Metronidazole
Metronidazole may increase the QTc-prolonging activities of Procainamide.
Midostaurin
The metabolism of Procainamide can be decreased when combined with Midostaurin.
Mifepristone
Procainamide may increase the QTc-prolonging activities of Mifepristone.
Mirabegron
Mirabegron may increase the QTc-prolonging activities of Procainamide.
Mirtazapine
Mirtazapine may increase the QTc-prolonging activities of Procainamide.
Mivacurium
Procainamide may increase the neuromuscular blocking activities of Mivacurium.
Moexipril
Moexipril may increase the QTc-prolonging activities of Procainamide.
Moxifloxacin
Moxifloxacin may increase the QTc-prolonging activities of Procainamide.
Nelfinavir
Nelfinavir may increase the QTc-prolonging activities of Procainamide.
Nevirapine
The metabolism of Procainamide can be decreased when combined with Nevirapine.
Nicardipine
Nicardipine may increase the QTc-prolonging activities of Procainamide.
Nilotinib
The risk or severity of QTc prolongation can be increased when Procainamide is combined with Nilotinib.
Norfloxacin
Norfloxacin may increase the QTc-prolonging activities of Procainamide.
Nortriptyline
Nortriptyline may increase the QTc-prolonging activities of Procainamide.
Octreotide
Octreotide may increase the QTc-prolonging activities of Procainamide.
Ofloxacin
Ofloxacin may increase the QTc-prolonging activities of Procainamide.
Olanzapine
Olanzapine may increase the QTc-prolonging activities of Procainamide.
Olodaterol
Olodaterol may increase the QTc-prolonging activities of Procainamide.
Ondansetron
Ondansetron may increase the QTc-prolonging activities of Procainamide.
Oxytocin
Oxytocin may increase the QTc-prolonging activities of Procainamide.
Paliperidone
The risk or severity of QTc prolongation can be increased when Procainamide is combined with Paliperidone.
Pancuronium
Procainamide may increase the neuromuscular blocking activities of Pancuronium.
Pancuronium Bromide
Procainamide may increase the neuromuscular blocking activities of Pancuronium.
Panobinostat
The serum concentration of Procainamide can be increased when it is combined with Panobinostat.
Paroxetine
The metabolism of Procainamide can be decreased when combined with Paroxetine.
Pasireotide
Pasireotide may increase the QTc-prolonging activities of Procainamide.
Pazopanib
Pazopanib may increase the QTc-prolonging activities of Procainamide.
Peginterferon Alfa-2b
The serum concentration of Procainamide can be decreased when it is combined with Peginterferon alfa-2b.
Pentamidine
Pentamidine may increase the QTc-prolonging activities of Procainamide.
Perflutren
Perflutren may increase the QTc-prolonging activities of Procainamide.
Pimozide
The risk or severity of QTc prolongation can be increased when Procainamide is combined with Pimozide.
Pipecuronium
Procainamide may increase the neuromuscular blocking activities of Pipecuronium.
Posaconazole
Posaconazole may increase the QTc-prolonging activities of Procainamide.
Primaquine
Primaquine may increase the QTc-prolonging activities of Procainamide.
Promazine
Promazine may increase the QTc-prolonging activities of Procainamide.
Promethazine
Promethazine may increase the QTc-prolonging activities of Procainamide.
Propafenone
Propafenone may increase the QTc-prolonging activities of Procainamide.
Propofol
Propofol may increase the QTc-prolonging activities of Procainamide.
Protriptyline
Protriptyline may increase the QTc-prolonging activities of Procainamide.
Pyrantel
Procainamide may increase the neuromuscular blocking activities of Pyrantel.
Quetiapine
The risk or severity of QTc prolongation can be increased when Procainamide is combined with Quetiapine.
Quetiapine fumarate
The risk or severity of QTc prolongation can be increased when Procainamide is combined with Quetiapine.
Quinidine
The risk or severity of QTc prolongation can be increased when Quinidine is combined with Procainamide.
Quinine
The risk or severity of QTc prolongation can be increased when Quinine is combined with Procainamide.
Ranitidine
The serum concentration of Procainamide can be increased when it is combined with Ranitidine.
Ranolazine
Ranolazine may increase the QTc-prolonging activities of Procainamide.
Rapacuronium
Procainamide may increase the neuromuscular blocking activities of Rapacuronium.
Ribociclib
The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Procainamide.
Rilpivirine
Rilpivirine may increase the QTc-prolonging activities of Procainamide.
Risperidone
Risperidone may increase the QTc-prolonging activities of Procainamide.
Ritonavir
The metabolism of Procainamide can be decreased when combined with Ritonavir.
Rocuronium
Procainamide may increase the neuromuscular blocking activities of Rocuronium.
Rolapitant
The metabolism of Procainamide can be decreased when combined with Rolapitant.
Ropinirole
The metabolism of Procainamide can be decreased when combined with Ropinirole.
Rucaparib
The metabolism of Procainamide can be decreased when combined with Rucaparib.
Salmeterol
Salmeterol may increase the QTc-prolonging activities of Procainamide.
Saquinavir
Saquinavir may increase the QTc-prolonging activities of Procainamide.
Saquinavir Mesylate
Saquinavir may increase the QTc-prolonging activities of Procainamide.
Sertraline
Sertraline may increase the QTc-prolonging activities of Procainamide.
Sevoflurane
Sevoflurane may increase the QTc-prolonging activities of Procainamide.
Solifenacin
Solifenacin may increase the QTc-prolonging activities of Procainamide.
Sorafenib
Sorafenib may increase the QTc-prolonging activities of Procainamide.
Sotalol
The risk or severity of QTc prolongation can be increased when Sotalol is combined with Procainamide.
Succinylcholine
Procainamide may increase the neuromuscular blocking activities of Succinylcholine.
Sulfamethoxazole
Sulfamethoxazole may increase the QTc-prolonging activities of Procainamide.
Sulfisoxazole
Sulfisoxazole may increase the QTc-prolonging activities of Procainamide.
Sulpiride
The risk or severity of adverse effects can be increased when Procainamide is combined with Sulpiride.
Sunitinib
Sunitinib may increase the QTc-prolonging activities of Procainamide.
Tamoxifen
Tamoxifen may increase the QTc-prolonging activities of Procainamide.
Telavancin
Telavancin may increase the QTc-prolonging activities of Procainamide.
Telithromycin
Telithromycin may increase the QTc-prolonging activities of Procainamide.
Terbinafine
The metabolism of Procainamide can be decreased when combined with Terbinafine.
Terbutaline
Terbutaline may increase the QTc-prolonging activities of Procainamide.
Terbutaline Sulfate
Terbutaline may increase the QTc-prolonging activities of Procainamide.
Tetrabenazine
The risk or severity of QTc prolongation can be increased when Procainamide is combined with Tetrabenazine.
Thioridazine
The risk or severity of QTc prolongation can be increased when Thioridazine is combined with Procainamide.
Thiothixene
Thiothixene may increase the QTc-prolonging activities of Procainamide.
Ticlopidine
The metabolism of Procainamide can be decreased when combined with Ticlopidine.
Tipranavir
The metabolism of Procainamide can be decreased when combined with Tipranavir.
Tizanidine
Tizanidine may increase the QTc-prolonging activities of Procainamide.
Tolterodine
Tolterodine may increase the QTc-prolonging activities of Procainamide.
Toremifene
The risk or severity of QTc prolongation can be increased when Toremifene is combined with Procainamide.
Tranylcypromine
The metabolism of Procainamide can be decreased when combined with Tranylcypromine.
Trazodone
Trazodone may increase the QTc-prolonging activities of Procainamide.
Treprostinil
Treprostinil may increase the QTc-prolonging activities of Procainamide.
Trimethoprim
The serum concentration of the active metabolites of Procainamide can be increased when Procainamide is used in combination with Trimethoprim.
Trimipramine
Trimipramine may increase the QTc-prolonging activities of Procainamide.
Triptorelin
Triptorelin may increase the QTc-prolonging activities of Procainamide.
Tubocurarine
Procainamide may increase the neuromuscular blocking activities of Tubocurarine.
Vandetanib
The risk or severity of QTc prolongation can be increased when Procainamide is combined with Vandetanib.
Vardenafil
Vardenafil may increase the QTc-prolonging activities of Procainamide.
Vecuronium
Procainamide may increase the neuromuscular blocking activities of Vecuronium.
Vemurafenib
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Procainamide.
Venlafaxine
Venlafaxine may increase the QTc-prolonging activities of Procainamide.
Vilanterol
Vilanterol may increase the QTc-prolonging activities of Procainamide.
Voriconazole
Voriconazole may increase the QTc-prolonging activities of Procainamide.
Vorinostat
Vorinostat may increase the QTc-prolonging activities of Procainamide.
Ziprasidone
The metabolism of Procainamide can be decreased when combined with Ziprasidone.
Zuclopenthixol
The risk or severity of QTc prolongation can be increased when Procainamide is combined with Zuclopenthixol.
